Drugmaker CEOs are skeptical of Silicon Valley’s promise that AI will cure disease, with reader discussion questioning how many concrete life-saving breakthroughs AI has delivered so far—AlphaFold is often cited, but commenters say the evidence remains limited. Readers argue AI can still help by improving diagnosis, analyzing research and patient data, and matching treatments without needing to cure disease outright. They also warn that AI could accelerate pharma work but may amplify centralized reasoning, political bias, and research monoculture.